Evidence map›Paper›PMID 39355021›Full record

ArticleFrontiers in nuclear medicine2023

The complementary role of MRI and FET PET in high-grade gliomas to differentiate recurrence from radionecrosis.

Arpita Sahu, Ronny Mathew, Renuka Ashtekar, Archya Dasgupta, Ameya Puranik, Abhishek Mahajan, Amit Janu, Amitkumar Choudhari, Subhash Desai, Nandakumar G Patnam and 12 more

Abstract read
In one paragraph

Article in Frontiers in nuclear medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Chemically stabilized MgFRSC advances · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Arpita SahuDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Ronny MathewDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Renuka AshtekarDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Archya DasguptaDepartment of Radiation Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Ameya PuranikDepartment of Nuclear Medicine, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Abhishek MahajanDepartment of Radiology, The Clatterbridge Cancer Centre NHS Foundation Trust, Pembroke Place, Liverpool, United Kingdom.
Amit JanuDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Amitkumar ChoudhariDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Subhash DesaiDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Nandakumar G PatnamDepartment of Radiodiagnosis, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Abhishek ChatterjeeDepartment of Radiation Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Vijay PatilDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Nandini MenonDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Yash JainDepartment of Nuclear Medicine, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Venkatesh RangarajanDepartment of Nuclear Medicine, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Indraja DevDepartment of Nuclear Medicine, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Sridhar EpariDepartment of Pathology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Ayushi SahayDepartment of Pathology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Prakash ShettyDepartment of Neurosurgery, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Jayant GodaDepartment of Radiation Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Aliasgar MoiyadiDepartment of Neurosurgery, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
Tejpal GuptaDepartment of Radiation Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Conventional magnetic resonance imaging (MRI) has limitations in differentiating tumor recurrence (TR) from radionecrosis (RN) in high-grade gliomas (HGG), which can present with morphologically similar appearances. Multiparametric advanced MR sequences and Positron Emission Tomography (PET) with amino acid tracers can aid in diagnosing tumor metabolism. The role of both modalities on an individual basis and combined performances were investigated in the current study. Materials and Methods: Patients with HGG with MRI and PET within three weeks were included in the retrospective analysis. The multiparametric MRI included T1-contrast, T2-weighted sequences, perfusion, diffusion, and spectroscopy. MRI was interpreted by a neuroradiologist without using information from PET imaging. 18F-Fluoroethyl-Tyrosine (FET) uptake was calculated from the areas of maximum enhancement/suspicion, which was assessed by a nuclear medicine physician (having access to MRI to determine tumor-to-white matter ratio over a specific region). A definitive diagnosis of TR or RN was made based on the combination of multidisciplinary joint clinic decisions, histopathological examination, and clinic-radiological follow-up as applicable. Results: 62 patients were included in the study between July 2018 and August 2021. The histology during initial diagnosis was glioblastoma, oligodendroglioma, and astrocytoma in 43, 7, and 6 patients, respectively, while in 6, no definitive histological characterization was available. The median time from radiation (RT) was 23 months. 46 and 16 patients had TR and RN recurrence, respectively. Sensitivity, specificity, and accuracy using MRI were 98, 77, and 94%, respectively. Using PET imaging with T/W cut-off of 2.65, sensitivity, specificity, and accuracy were 79, 84, and 80%, respectively. The best results were obtained using both imaging combined with sensitivity, specificity, and accuracy of 98, 100, and 98%, respectively. Conclusion: Combined imaging with MRI and FET-PET offers multiparametric assessment of glioma recurrence that is correlative and complimentary, with higher accuracy and clinical value.

Indexed as

biological imagingglioblastomahigh-grade gliomaMRIPETradionecrosisrecurrence

Identifiers

PMID39355021
PMCPMC11440952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.